


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29729/37581Serial No.
09/889,075

INFORMATION DISCLOSURE STATEMENT

Applicant
Atkins et al.Filing Date
01/11/00Group
Not yet assigned

Use several sheets if necessary



FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
JDS	B1	WO 96/17086	06/06/96	PCT				
↓	B2	WO 97/32979	09/12/97	PCT				
	B3	WO 98/49346	11/05/98	PCT				
↓	B4	WO 99/50452	10/07/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JDS	C1	Cairns <i>et al.</i> , "Target Site Selection for an RNA-Cleaving Catalytic DNA" <i>Nature Biotechnology</i> , Vol. 17, pp. 480-486, May 1999
↓	C2	Milbrandt, J. Rat nerve growth factor-induced (NGFI-A) gene complete cds. 1987. Genbank Accession No. M18416
	C3	Santiago <i>et al.</i> , "New DNA Enzyme Targeting Egr-1 mRNA Inhibits Vascular Smooth Muscle Proliferation and Regrowth After Injury" <i>Nature Medicine</i> ; Vol. 5, No. 11, pp. 1264-1269, November 1999
	C4	Santoro <i>et al.</i> , "Mechanism and Utility of an RNA-Cleaving DNA Enzyme" <i>Biochemistry</i> , Vol. 37, No. 38, pp. 13330-13342, 1998
	C5	Santoro <i>et al.</i> , "A General Purpose RNA-Cleaving DNA Enzyme" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 4262-4266, April 1997
↓	C6	Sukhatme, V.P. Human mRNA for early growth response Protein 1 (hEGR1). 1990. Genbank Accession No. X52541

EXAMINER

/James Schultz/

DATE CONSIDERED

07/27/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



BN/SB/08A/B

Substitute for form 1449A/US

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/889,075
Filing Date	September 9, 2002
First Named Inventor	ATKINS
Group Art Unit	
Examiner Name	
Attorney Docket Number	ATKINS1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JDS	AA	PEREZ-CASTILLO A et al "NGFI-A Gene Expression is Necessary for T Lymphocyte Proliferation" Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US. Vol 268, No. 26, (September 15, 1993) pp: 19445-19450	
	AB	RUPPRECHT H D et al "Der Transkriptionsfaktor EGR-1 Reguliert Das Wachstum Glomerulaerer Mesangiumzellen The Transcriptional Regulator EGR-1 and Growth Control of GL Omerula Mesangial Cells" Medizinische Klinik, Vol 92, No. 2 (1997) pp:68-73	
	AC	SACHINIDIS AGAPIOS et al "Oligodeoxynucleotides directed to early growth response gene-1 mRNA inhibit DNA synthesis in the smooth muscle cell" European Journal of Pharmacology, Vol. 309, No.1 (1996) pp: 95-105	
	AD	DATABASE EMBL 'Online! (July 6, 1989) "Rattus norvegicus nerve growth factor (NGF-1A) gene, complete cds" XP002303013 retrieved from EBI accession no. EM_PRO:RNNGF1A Database accession no. J04154	

Examiner
Signature

/James Schultz/

Date
Considered

07/27/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete If Known

Application Number	09/889,075
Filing Date	September 9, 2002
First Named Inventor	David G. ATKINS
Group Art Unit	1635
Examiner Name	James Shultz
Attorney Docket Number	ATKINS1


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JDS	AE	ADAMIS, A. P., et al., "Angiogenesis and Ophthalmic Disease", Angiogenesis, 1999, Vol. 3, pages 9-14	
	AF	BHUSHAN, M., "Recent Advances in Cutaneous Angiogenesis", British Journal of Dermatology, 2002, Vol. 147, pages 418-425	
	AG	DIGHTL, W., et al., "HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in human Endothelial and Vascular Smooth Muscle Cells", Arterioscler Thromb Vasc. Biol., January 2003, pages 58-63	
	AH	FAHMY, R. G., et al., "Locked Nucleic Acid Modified DNA Enzymes Targeting Early Growth Response-1 Inhibit Human Vascular Smooth Muscle Cell Growth", Nucleic Acids Research, 2004, Vol. 32, No. 7, pages 2281-2285	
	AI	FAHMY, R. G., et al., "Transcription Factor Egr-1 Supports FGF-Dependent Angiogenesis During Neovascularization and Tumor Growth", Nature Medicine, August 2003, Vol. 9, No. 8, pages 1026-1032	
	AJ	FERRARA, N., et al., "The Biology of VEGF and Its Receptors" Nature Medicine, June 2003, Vol. 9, No. 6, pages 669-676	
	AK	HOFER, G., et al., "Transcription Factor Egr-1 Regulates Glomerular Mesangial Cell Proliferation", The Journal of Biological Chemistry, November 8, 1996, Vol. 271, No. 45, pages 28306-28310	
	AL	ITO, Y., et al., "Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4" Cancer Research, October 15, 2003, Vol. 63, pages 6651-6657	
	AM	JANSSEN, Y., et al., "Differential Induction of c-fos, c-jun, and apoptosis in Lung Epithelial Cells Exposed to ROS or RNS", 1997, pages L789-L796	
	AN	KRZYSTOLIK, M. G., et al., "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment", Arch. Ophthalmol., March 2002, Vol. 120, pages 338-346	
	AO	KUKITA, T., et al., "Regulation of Osteoclastogenesis by Antisense Oligodeoxynucleotide Specific to Zinc Finger Nuclear transcription Factors Egr-1 and WT1 in Rat Bone Marrow Culture System", Endocrinology, 1997, Vol. 138, No. 10, pages 4384-4389	
	AP	KURRECK, J., et al., "Comparative Study of DNA Enzymes and Ribozymes against the Same Full-Length Messenger RNA of the Vanilloid Receptor Subtype I", The Journal of Biological Chemistry, March 1, 2002, Vol. 277, No. 9, pages 7099-7107	
	AQ	LEENDERS, W., et al., "Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1", Laboratory Investigation, April 2002, Vol. 82, No. 4, pages 473-481	
✓	AR	MALDVE, R. E., et al., "Tumor-Promoting Activity of 2,4-Dinitrofluorobenzene", Int. Journal Cancer, 1995, Vol. 60, pages 545-553	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/889,075</td> </tr> <tr> <td>Filing Date</td> <td>September 9, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>David G. ATKINS</td> </tr> <tr> <td>Group Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>James Shultz</td> </tr> <tr> <td>Attorney Docket Number</td> <td>ATKINS1</td> </tr> </table>		Application Number	09/889,075	Filing Date	September 9, 2002	First Named Inventor	David G. ATKINS	Group Art Unit	1635	Examiner Name	James Shultz	Attorney Docket Number	ATKINS1
Application Number	09/889,075														
Filing Date	September 9, 2002														
First Named Inventor	David G. ATKINS														
Group Art Unit	1635														
Examiner Name	James Shultz														
Attorney Docket Number	ATKINS1														
Sheet	2	of	2												



JDS	AS	MITCHELL A., et al., "Inhibition of Human Breast Carcinoma Proliferation, Migration, Chemoinvasion and Solid Tumor Growth by DNazymes Targeting The Zinc Finger Transcription Factor EGR-1", Nucleic Acids Research, 2004, Vol. 32, No. 10, pages 3065-3069	
	AT	MOMIYAMA, N., et al., "Suppression of <i>c-jun</i> by Antisense Oligonucleotide Inhibits Cell Adhesion but not Respiratory Burst During Phorbol Ester-Induced Differentiation of U937 Human Monoblastic Cells", Cell Growth & Differentiation, August 1996, Vol. 7, pages 1006-1012	
	AU	NAKAMURA, H., et al., "Introduction of DNA Enzyme for Egr-1 Into Tubulointerstitial Fibroblasts by Electroporation Reduced Interstitial α -smooth Muscle Actin Expression and Fibrosis in Unilateral Ureteral Obstruction (UUO) Rats" Gene Therapy, 2002, Vol. 9, pages 495-502	
	AV	NGUYEN, H. Q., et al., "The Zinc Finger Transcription Factor Egr-1 Is Essential for and Restricts Differentiation Along the Macrophage Lineage", Cell, January 29, 1993, Vol. 72, pages 197-209	
	AW	PAN, W., et al., "Identification of Efficient Cleavage Sites in Long-Target RNAs", Ribozymes and siRNA Protocols Second Edition; Methods in Molecular Biology, 2004, Vol 252, pages 125-144	
	AX	ROSS, R., "Atherosclerosis - An Inflammatory Disease" Mechanisms of Disease, January 14, 1999, Vol. 340, No. 2, pages 115-126	
	AY	SANTORO, S., et al., "A General Purpose RNA-Cleaving DNA Enzyme", Pro. Natl. Acad., Sci. USA, April 1997, Vol. 94, pages 4262-4266	
	AZ	SCHERER, L. J., et al., "Approaches for the Sequence-Specific Knockdown of mRNA", Nature Biotechnology, December 2003, Vol. 21, No. 12, pages 1457-1465	
	BA	SELLS, S. F., et al., "The Zinc Finger Transcription Factor EGR-1 Impedes Interleukin-1-Inducible Tumor Growth Arrest", Molecular Cellular Biology, February 1995, Vol. 15, No. 2, pages 682-692	
	BB	SUGGS, S. V., et al., "cDNA Sequence of the Human Cellular Early Growth Response Gene Egr-1", Nucleic Acids Research, April 13, 1990, Vol. 18, No. 14, EMBL accession no. X52541, page 4283	
	BC	VAN NIEUW AMERONGEN, G. P., et al., "Targets of Pharmacological Intervention of Endothelial Hyperpermeability and Barrier Function", Vascular Pharmacology, 2003, Vol. 39, pages 257-272	
	BD	WANG, N., et al., "Adenovirus-Mediated Overexpression of Dominant-Negative Mutant of C-Jun Prevents Intercellular Adhesion Molecule-1 Inductionn by LDL", Arterioscler Thromb Vasc Biol., September 2001, pages 1414-1420	
	BE	YAMADA, M., "Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor", Arterioscler Thromb Vasc Biol., November 2003, pages 1996-2001	
	BF	YOKOTA, T., et al., "siRNA-Based Inhibition Specific for Mutant SOD1 with Single Nucleotide Alternation in Familial ALS, Compared with Ribozyme and DNA Enzyme", Biochemical and Biophysical Research Communications, 2004, Vol. 314, pages 283-291	
V	BG	ZHANG, G., et al., "Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents", Journal of the National Cancer Institute, May 5, 2004, Vol. 96, No. 9, pages 683-696	

Examiner Signature	/James Schultz/	Date Considered	07/27/2006
--------------------	-----------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.